» Articles » PMID: 8425562

Hematopoietic Stem Cells Engraft in Untreated Transplant Recipients

Overview
Journal Exp Hematol
Specialty Hematology
Date 1993 Feb 1
PMID 8425562
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated the engraftment of hematopoietic stem cells in completely untreated transplant recipients to further study hematopoietic cell regulation and for possible inclusion in gene therapy protocols. Untreated female Balb/c recipients received a single infusion of male Balb/c marrow cells. Donor origin of the hematopoietic cells was determined by polymerase chain reaction (PCR), Southern and in situ hybridization analyses with Y-chromosome-specific probes. We found that up to 47% day 12 CFU-S (26.2 +/- 12.6%, mean +/- SD, range 13.3 to 46.7%), 7.3 +/- 5.5% CFU-GM and from 2.5 to approximately 10% nucleated marrow cells were of donor-origin at 8 weeks after marrow infusion. Our results indicate that hematopoietic stem cells can stably engraft in completely unconditioned recipients but, during the interval analyzed, have a low tendency to differentiate. Moreover, the data suggest that under steady-state conditions, niches for primitive hematopoietic cells present in the marrow microenvironment are not saturated, and are readily available. We conclude that the untreated-recipient transplant model, in conjunction with sensitive techniques for the detection of donor cells, provides a valuable means for studying hematopoietic stem cell regulation and indicates a need to reassess our understanding of the interactions between stem cells and the hematopoietic microenvironment.

Citing Articles

The Influence of Heterochronic Non-Myeloablative Bone Marrow Transplantation on the Immune System, Frailty, General Health, and Longevity of Aged Murine Recipients.

Jazbec K, Jez M, Svajger U, Smrekar B, Miceska S, Rajcevic U Biomolecules. 2022; 12(4).

PMID: 35454183 PMC: 9028083. DOI: 10.3390/biom12040595.


Immunoresponse to Gene-Modified Hematopoietic Stem Cells.

Drysdale C, Tisdale J, Uchida N Mol Ther Methods Clin Dev. 2019; 16:42-49.

PMID: 31763350 PMC: 6859277. DOI: 10.1016/j.omtm.2019.10.010.


Bone marrow chimeras in the study of experimental stroke.

Tang X, Zheng Z, Yenari M Transl Stroke Res. 2013; 3(3):341-7.

PMID: 24323809 DOI: 10.1007/s12975-012-0169-6.


Purified hematopoietic stem cell transplantation: the next generation of blood and immune replacement.

Czechowicz A, Weissman I Hematol Oncol Clin North Am. 2011; 25(1):75-87.

PMID: 21236391 PMC: 4126902. DOI: 10.1016/j.hoc.2010.11.006.


Bone marrow-derived stem cell transplantation for the treatment of insulin-dependent diabetes.

Fotino C, Ricordi C, Lauriola V, Alejandro R, Pileggi A Rev Diabet Stud. 2010; 7(2):144-57.

PMID: 21060973 PMC: 2989787. DOI: 10.1900/RDS.2010.7.144.